Clinical trials are an important option for patients because the newest treatment approaches, not available otherwise, are being tested in them. Clinical trial research leads to more advancements and potential treatment options, and the therapies used today were once tested in clinical trials. Continued progress is only possible if patients with lung cancer volunteer to participate in the clinical trial process. 

LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research,  discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies.  Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr.

The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.

During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.

Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers you need. Being prepared may also lessen anxiety and help provide a sense of control. Meeting with your oncologist, especially when first diagnosed or deciding on a treatment plan, are times when being prepared with questions is necessary.  

Targeted therapies, or treatments directed towards specific biomarkers in tumor cells, have been effective in treating many patients with advanced-stage non-small cell lung cancer (NSCLC).

Brain metastases are known to occur in approximately 25% of patients diagnosed with lung cancer. This webinar dives into the details of brain metastasis in lung cancer to explore their signs and symptoms. It also includes a discussion of treatment considerations.

Through this webinar, you will learn to:

Pulmonary rehab expert Debbie Koehl, MS, RRT-NPS, AE-C, FAARC, speaks to LUNGevity's Survivorship Navigator, Kristi Griffith, to explain what pulmonary rehabilitation is, explore the benefits of pulmonary rehabilitation, and gain key insights about how to obtain pulmonary rehabilitation for yourself or a loved one. The discussion is followed by an informal Q&A with other lung cancer survivors. This recording was made during one of LUNGevity Foundation's Virtual Meetups -- a free resource for the lung cancer community.

In this video, nurse practitioner Lauren Welch, MSN, NP-C, AOCNP, from the Sarah Cannon Research Institute at Tennessee Oncology offers a quick review of pneumonitis - a common side effect of some lung cancer treatments. Survivors and caregivers can learn: What is pneumonitis? What causes it? How is it treated? What symptoms should we look out for?

LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director of Research, interviewed Hilary Hammell (RETpositive) and Dr. Alexandre Reuben (MD Anderson Cancer Center) about an exciting project on using the immune system to treat RET-positive lung cancer. This project is being funded by the RETpositive patient group. This interview was live on Facebook on October 18; watch the video here.

Lung cancer survivor Jill Feldman joins radiation therapy experts Drs. Drew Moghanaki and Kristin Higgins to provide an overview of radiation therapy – including discussions of when this treatment is recommended, how the treatment is administered, and which side effects are most common.